TNX-103 (oral levosimendan)
Pulmonary Hypertension due to Heart Failure with preserved Ejection Fraction (PH-HFpEF)
Key Facts
Indication
Pulmonary Hypertension due to Heart Failure with preserved Ejection Fraction (PH-HFpEF)
Phase
Phase 3
Status
Active - Recruiting
Company
About Tenax Therapeutics
Tenax Therapeutics is on a mission to address the critical unmet need in PH-HFpEF, the most common form of pulmonary hypertension globally. Its strategy centers on the targeted repurposing of levosimendan, developing an oral formulation (TNX-103) for chronic use based on the drug's well-known safety profile and promising early clinical data in PH-HFpEF. The company is led by a veteran management team with deep cardiovascular development experience and is currently executing a Phase 3 clinical program designed to derisk the path to potential regulatory approval.
View full company profile